First-line immune-based combination therapies for advanced non-small cell lung cancer: A Bayesian network meta-analysis.

ABSTRACT:

Background

Immune-based combination therapies have revolutionized the first-line treatment for advanced non-small cell lung cancer (NSCLC). However, for the efficacy and safety, the best treatment option is still uncertain.

Methods

We conducted a Bayesian network meta-analysis of randomized controlled trials (RCTs) to evaluate first-line immune-based combination therapies for advanced NSCLC.

Results

Fourteen trials involving 8467 patients were included. For the programmed cell death-ligand 1 (PD-L1) expression non-selective patients, there were no significant differences among all the treatment modes for overall survival (OS), but the ranking profiles indicated that Immunotherapy + Immunotherapy + Chemotherapy (IO + IO + Chemo) was most likely to be the best mode (pro

SUBMITTER: Mao Z 

PROVIDER: S-EPMC8683544 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature